MIM
ZNTL icon

MetLife Investment Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

MetLife Investment Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,971
Closed -$69.6K – 2828
2024
Q4 		$69.6K Sell
22,971
-11,119
-33% -$36.4K ﹤0.01% 2710
2024
Q3 		$125K Hold
34,090
– – ﹤0.01% 2533
2024
Q2 		$139K Buy
34,090
+3,388
+11% +$37.8K ﹤0.01% 2447
2024
Q1 		$484K Hold
30,702
– – ﹤0.01% 1693
2023
Q4 		$465K Hold
30,702
– – ﹤0.01% 1734
2023
Q3 		$616K Buy
30,702
+5,158
+20% +$131K ﹤0.01% 1501
2023
Q2 		$721K Buy
25,544
+608
+2% +$14.6K 0.01% 1455
2023
Q1 		$429K Hold
24,936
– – ﹤0.01% 1736
2022
Q4 		$502K Hold
24,936
– – ﹤0.01% 1643
2022
Q3 		$540K Buy
24,936
+5,271
+27% +$144K ﹤0.01% 1584
2022
Q2 		$553K Hold
19,665
– – ﹤0.01% 1583
2022
Q1 		$907K Buy
19,665
+7,139
+57% +$385K 0.01% 1395
2021
Q4 		$1.05M Hold
12,526
– – 0.01% 1107
2021
Q3 		$835K Buy
12,526
+678
+6% +$39.1K 0.01% 1219
2021
Q2 		$630K Hold
11,848
– – 0.01% 1435
2021
Q1 		$514K Hold
11,848
– – ﹤0.01% 1506
2020
Q4 		$615K Buy
11,848
+6,771
+133% +$305K 0.01% 1373
2020
Q3 		$166K Sell
5,077
-5,077
-50% -$178K ﹤0.01% 1974
2020
Q2 		$488K Buy
+10,154
New +$389K 0.01% 1395

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's ZNTL Position: Q1 2025 in Review

MetLife Investment Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 22,971 shares — an estimated $69.6K sold.

MetLife Investment Management first reported a position in ZNTL in Q2 2020 and held it in 19 quarters. The position peaked at $1.05M in Q4 2021. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • MetLife Investment Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 22,971 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $69.6K.
  • MetLife Investment Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • MetLife Investment Management's Zentalis Pharmaceuticals position peaked at $1.05M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.